Hologic (NASDAQ:HOLX) CEO Stephen Macmillan Sells 138,358 Shares

Key Points

• Hologic CEO Stephen Macmillan sold 138,358 shares of the company's stock for approximately $9.27 million, reducing his ownership by 10.08% to about 1.23 million shares.
• Hologic reported $1.02 billion in revenue during its last quarter, exceeding analyst expectations by $0.01, and had an earnings per share (EPS) of $1.08.
• The company recently received several analyst upgrades, with price targets ranging from $70.00 to $87.00, indicating a generally positive outlook on the stock's performance.

Hologic, Inc. (NASDAQ:HOLX - Get Free Report) CEO Stephen Macmillan sold 138,358 shares of the firm's stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the transaction, the chief executive officer owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Hologic Stock Performance

Shares of NASDAQ HOLX traded up $0.35 during mid-day trading on Tuesday, reaching $67.64. 1,760,389 shares of the company's stock were exchanged, compared to its average volume of 2,703,988. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.39. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The firm has a market capitalization of $15.04 billion, a price-to-earnings ratio of 28.07, a price-to-earnings-growth ratio of 2.40 and a beta of 0.57. The firm has a 50-day moving average price of $66.53 and a two-hundred day moving average price of $62.77.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. The business had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business's quarterly revenue was up 1.2% on a year-over-year basis. During the same period last year, the business earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Hedge Funds Weigh In On Hologic

Large investors have recently bought and sold shares of the business. Chung Wu Investment Group LLC acquired a new position in Hologic during the 2nd quarter valued at about $26,000. Caitong International Asset Management Co. Ltd increased its position in Hologic by 193.6% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider's stock valued at $27,000 after buying an additional 273 shares in the last quarter. Loomis Sayles & Co. L P acquired a new position in shares of Hologic in the second quarter valued at about $33,000. Zions Bancorporation National Association UT acquired a new position in shares of Hologic in the first quarter valued at about $34,000. Finally, Cromwell Holdings LLC increased its holdings in shares of Hologic by 307.0% in the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider's stock valued at $38,000 after purchasing an additional 436 shares during the period. Hedge funds and other institutional investors own 94.73% of the company's stock.

Analyst Upgrades and Downgrades

HOLX has been the subject of a number of research analyst reports. UBS Group raised their price target on Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a research note on Thursday, July 31st. Royal Bank Of Canada upgraded Hologic from a "sector perform" rating to an "outperform" rating and increased their price objective for the stock from $72.00 to $87.00 in a report on Wednesday, August 6th. Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Evercore ISI increased their price objective on Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a report on Tuesday, July 8th. Finally, Morgan Stanley raised their price target on Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a report on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $79.38.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.